Oprean, C.M.; Badau, L.M.; Petrita, R.; Median, M.D.; Dema, A.
Real-World, National Study of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021. Diagnostics 2025, 15, 1173.
https://doi.org/10.3390/diagnostics15091173
AMA Style
Oprean CM, Badau LM, Petrita R, Median MD, Dema A.
Real-World, National Study of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021. Diagnostics. 2025; 15(9):1173.
https://doi.org/10.3390/diagnostics15091173
Chicago/Turabian Style
Oprean, Cristina Marinela, Larisa Maria Badau, Ramona Petrita, Mircea Dragos Median, and Alis Dema.
2025. "Real-World, National Study of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021" Diagnostics 15, no. 9: 1173.
https://doi.org/10.3390/diagnostics15091173
APA Style
Oprean, C. M., Badau, L. M., Petrita, R., Median, M. D., & Dema, A.
(2025). Real-World, National Study of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021. Diagnostics, 15(9), 1173.
https://doi.org/10.3390/diagnostics15091173